The amino acid sequence of the heat-stable inhibitor of the cAMP-dependent protein kinase (PKI) was determined recently [Scott, J. D., Fischer, E. H., Takio, K., Demaille, J. G. & Krebs, E. G. (1985) Proc. Nail. Acad. Sci. USA 82, [5732][5733][5734][5735][5736]]. An earlier report Proc. Natd. Acad. Sci. USA 82, 43794383] showed that at least part of the inhibitory domain of PKI is located in a 20-residue segment extending from residue 11 to residue 30: lle-Ala-Ser-Gly-ArgThr-Gly-Arg-Arg-Asn-Ala-Ile-His-Asp-Ile-Leu-Val-Ser-SerAla. In the present study, we further mapped the inhibitory region of PKI by addition or deletion of residues at both ends of this peptide and by substitutions for specific amino acids. The results show that (i) deletion of residues 25-30 did not change inhibitory activity but addition of residues toward the amino terminus increased the inhibitory potency up to 150-fold (K, 4.8 nM), to a level approaching that of PKI; (u) replacement of alanine-21 by serine converted the inhibitor into a substrate having a relatively low affmnity (Km 280 WM) for the enzyme;
Thr-Gly-Arg-Arg-Asn-Ala-Ile-His-Asp-Ile-Leu-Val-Ser-SerAla. In the present study, we further mapped the inhibitory region of PKI by addition or deletion of residues at both ends of this peptide and by substitutions for specific amino acids. The results show that (i) deletion of residues 25-30 did not change inhibitory activity but addition of residues toward the amino terminus increased the inhibitory potency up to 150-fold (K, 4.8 nM) , to a level approaching that of PKI; (u) replacement of alanine-21 by serine converted the inhibitor into a substrate having a relatively low affmnity (Km 280 WM) for the enzyme;
(fib) replacement of alanine-21 by phosphoserine or aaminobutyric acid decreased inhibitory activity by a factor of 120 and 20, respectively; (iv) replacement of serine-13 had essentially no effect, whereas substitution of threonine-16 decreased inhibitory activity. The greatest decreases of inhibitory potency occurred with replacements of the arginines in positions 18 and 19. The heat-stable inhibitor of cAMP-dependent protein kinase (PKI) is a potent inhibitor of the enzyme (1) (2) (3) (4) (5) . It interacts specifically (2, 3) and competitively (4, 6) with the free catalytic subunit of the kinase (C) formed by dissociation of the holoenzyme (R2C2) by cAMP. Rabbit skeletal muscle PKI has been obtained in a homogeneous form by a procedure that employs harsh conditions, including heating at 900C and acid precipitation (4, 5) . Recently, the complete amino acid sequence of the inhibitor from rabbit skeletal muscle was determined by microsequencing techniques (7) . PKI contains 75 amino acids (Mr = 7829); its amino terminus is blocked. Sequence information confirmed earlier reports (4, 5) that it lacks tryptophan, proline, and sulfur-containing amino acids (7) . PKI is a very strong competitive inhibitor of C, exhibiting a Ki = 0.5-2 nM (4, 6) . This value is approximately four orders of magnitude lower than the Km for the synthetic peptide substrate Leu-Ala-Arg-Arg-Ala-Ser-Leu-Gly (Kemptide) commonly used to assay the enzyme (8) .
Several investigators have established that basic amino acid residues, in particular arginine side chains preceding the serine or threonine susceptible to phosphorylation, are essential substrate-recognition sites for the cAMP-dependent protein kinase (8) (9) (10) (11) (12) . A minimal substrate structure of Arg-Arg-Xaa-Ser-Yaa has been proposed (reviewed in ref. 13 ). The autophosphorylation site in the type II regulatory subunit of the cAMP-dependent protein kinase (RII) contains this structure in its "hinge region" (14) (15) (16) , and it is thought this segment ofRII interacts with C, contributing to inhibition of the latter. The interaction of PKI with C is similar to that of RII, in that arginine residues are essential (4, 6) .
In preliminary work (5) it was reported that 2 of the 4 arginine residues in PKI are located in the amino-terminal portion of the molecule, from which an inhibitory peptide could be derived by limited proteolysis (17) . The amino acid sequence of PKI (18, 19) has revealed the presence of a pseudosubstrate site, Arg-Arg-Asn-Ala-Ile, that shows similarity to the hinge regions of both types of regulatory subunits, RI and RII (18) . Proteolytic cleavage of PKI at arginines destroys its inhibitory activity. The assumption that the pseudosubstrate region is part of the inhibitory site was confirmed by synthesis of a 20-residue peptide (residues [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] that is a potent inhibitor with a Ki of 800 nM (7, 18, 19) .
In this report, the initial observation that the inhibitory site of PKI is located within a linear sequence covering the pseudosubstrate site has been extended. The inhibitory region has been delineated further by the study of synthetic peptide analogs; the contributions of basic and other specific side chains are examined. A minimal synthetic peptide that might serve as a useful tool for the replacement of PKI as an inhibitor of the cAMP-dependent protein kinase in vitro has been defined.
METHODS
Solid-Phase Peptide Synthesis. Peptides were synthesized on a Beckman 990B solid-phase peptide synthesizer (20) . More recently, synthesis was performed on an Applied Biosystems Ab430 automatic solid-phase peptide synthesizer as described (21) . Cleavage from the resin and deprotection were achieved by incubation in 75% HF/25% anisole for 30 min at 00C. The amount and composition of each peptide were confirmed by amino acid analysis using the Waters Picotag systems (22) . The amino acid sequence of each peptide was determined on a Beckman 890C liquid-phase peptide sequenator as described (23) .
Purification of Peptides. Once cleaved from the resin, the peptides were desalted on a 2.5 x 200 cm column of Sephadex G-10 equilibrated in 1% (vol/vol) acetic acid and then were lyophilized. After being dissolved in a minimal volume, peptides were purified further by reversed-phase HPLC using Vydac semipreparative 1.5 x 21 cm C4 columns coupled in tandem, with either an LKB 2150 or a Varian 5000 liquid chromatograph. In each case the solvent system was trifluoroacetic acid/acetonitrile and elution was by increasing acetonitrile concentration. The elution position of individual peptides was a function of their amino acid composition.
Abbreviations: PKI, heat-stable inhibitor of cAMP-dependent protein kinase; C, catalytic subunit of cAMP-dependent protein kinase; RII, regulatory subunit of type II cAMP-dependent protein kinase.
1613
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Proc. Natl. Acad. Sci. USA 83 (1986) Assays. Each peptide was assayed for its ability to inhibit the phosphorylation of the synthetic peptide Leu-Ala-ArgArg-Ala-Ser-Leu-Gly (Kemptide) by the cAMP-dependent protein kinase (19 (19) . The resulting fragments were separated by reversed-phase HPLC on two Vydac C4 columns (1.5 x 21 cm) in tandem, equilibrated in 0.1% trifluoroacetic acid, on an LKB 2150 liquid chromatograph; elution was carried out by increasing concentrations of acetonitrile.
Phosphorylation of Peptides. Peptides were incubated with 300 nM C for 18 hr with ATP. Excess ATP and ADP was removed by ion-exchange chromatography on a column (0.5 x 1 cm) of Dowex AG1X8 anion-exchange resin equilibrated in 30% (vol/vol) acetic acid. The phosphorylated peptide, which did not adhere to the column, was collected in the void volume and was lyophilized. RESULTS Substitution of Other Amino Acids for Alanine in the Pseudosubstrate Site of PKI. Utilizing variants of the previously determined (19) inhibitory region of PKI: Ile-Ala-SerGly-Arg-Thr-Gly-Arg-Arg-Asn-Ala-Ile-His-Asp-Ile-LeuVal-Ser-Ser-Ala [PKI- (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) -peptide], we undertook studies to determine what effect specific amino acid substitutions and other changes would have on its ability to inhibit C. The first group of peptides studied were those in which alanine-21 of PKI (7) (18, 19) that is structurally similar to the hingeregions of both types of regulatory subunits (RI and RII) (15, 25) and several substrates of the kinase.
There are structural similarities between substrates and modulators of the protein kinase: they all possess a common site, the sequence Arg-Arg-Xaa-Ala/Ser-Yaa (13) . All kinase substrates have a serine or threonine one residue removed from two arginines, whereas both the type I regulatory subunit and PKI have alanine at this position. The minimal effective structure for synthetic peptide substrates is [6] [7] [8] [9] [10] residues long, while potent inhibitors contain at least [20] [21] [22] [23] [24] residues. This is evidenced by attempts to develop synthetic kinase inhibitors patterned after the heptapeptide substrate Kemptide (26, 27 (27) . Replacement of the pseudosubstrate-sequence alanine-21 with a-aminobutyric acid decreased the affinity by a factor of 20. This is not surprising, since introduction of an additional methyl group would make the pseudosubstrate side chain mimic that of threonine, which is often a less preferred substrate for C (11) . The kinase has decreased affinity for Kemptide analogs with threonine instead of serine (11) .
The detailed biophysical and kinetic studies by several investigators have suggested that substrate recognition by the kinase involves at least two independent steps, both of which can induce conformational changes at the ATP binding site (6, (28) (29) (30) (31) (32) . One is in response to a subsite of two basic residues, preferably arginines, and the other is due to the hydroxyl group of the target serine. Only the former changes in conformation can occur with inhibitory peptides, since the target hydroxyl group is not present.
Substitution of basic residues, in particular arginine-18 and -19, caused considerable decreases in affinity and may reflect the impaired ability of the positively charged subsite to interact with the kinase. The greatest decrease in affinity was associated with [Gly19]PKI-(7-30)-peptide, which was 1/520th as potent an inhibitor as the original peptide. This would suggest that arginine-19, the arginine closest to the pseudosubstrate alanine-21, is most important for inhibition.
Replacement of arginine-15 produced a lesser, though still significant, decrease in inhibition. Arginines at this position, 6 residues ahead of the target serine, are important for substrate recognition (12) . All protein modulators of cAMPdependent protein kinase (PKI, RI, and R11) fulfill this criterion (19, 33, 34) . Thus, an additional basic site is available for ionic interaction between the modulator proteins and C.
Residues 25-30 are not essential for inhibitory action, since they can be removed without loss of activity. For these experiments, aspartate-24 was replaced by glutamate to provide a better target for S. aureus V8 protease (35) . These data suggested that most recognition sites for the kinase would be located on the amino-terminal side of alanine-21. With this knowledge, a family of peptides of increasing size and extending toward the amino terminus of the protein were synthesized (Table 1) . Peptides beginning at tyrosine-7 displayed a modest increase in affinity (Ki 240 nM); surprisingly, deletion of aspartate-9 produced a more potent inhibitor (Ki 110 nM; data not shown). Aspartate-9 is clearly not essential for inhibition and may even serve as a negative determinant.
PKI is not phosphorylated (19) . Nevertheless, a peptide starting at tyrosine-7 was synthesized in which all serine and threonine residues were replaced. The purpose of this experiment was to develop a potent synthetic inhibitor that could not be phosphorylated by any serine or threonine protein kinase. Unfortunately, the affinity of the resulting peptide for C was decreased by a factor of 5. This may be partially explained by the increase in hydrophobicity provided by the substituted amino acids. A more likely hypothesis is that threonine-16 is important for kinase interaction. Such a conclusion can be drawn from the following consideration. Four (1986) native molecule. The cumulative effect of these two chemical modifications decreased the affinity for the kinase by a factor of 8. There are two possible explanations for these results: (i) PKI is blocked at its amino terminus by another group, or (it) some modification of serine and threonine side chains may have occurred even though acetylation was performed while the peptide was still bound to the resin and all potentially reactive groups should have been protected (36) .
Secondary-structure predictions by the method of Chou and Fasman (37) yielded little indication for an ordered conformation of PKI-(1-24)-peptide. Mildvan and coworkers (38) (39) (40) have proposed that bound peptide substrates assume an extended-coil conformation, which minimizes the number of interactions that may occur within the substrate and facilitates enzyme-substrate interaction. They concluded that this might contribute to kinase specificity (40) . It is likely that the same conformation is adopted by the pseudosubstrate site of PKI while selected amino acid side chains, located between residues 5 and 16, promote a high-affinity interactive surface with the kinase. Since all inhibitory activity is located in the amino-terminal portion of the molecule, the role ofthe remaining 50 residues is unclear. The carboxyl-terminal 50 residues might serve a stabilizing function-that is, protect the inhibitory domain from proteolytic degradation. Indeed, it has been observed that the synthetic inhibitory peptides described herein are highly susceptible to enzymatic cleavage and rapidly destroyed in vivo; for instance, when injected into Xenopus oocytes (M. Cicarelli and J.D.S., unpublished observation).
One of the major objectives in elucidating the amino acid sequence of PKI and locating its inhibitory domain was to determine a minimal structure that would retain strong inhibitory activity toward the kinase. This would then allow the large-scale production of a synthetic inhibitor. On the basis of the information gathered here, we conclude that the 20-residue PKI-(5-24)-peptide could well represent such a minimal structure. Although PKI-(1-24)-peptide is somewhat more potent as an inhibitor, the added complexity of synthesizing the longer peptide is greater than the advantage provided by a slight increase in affinity.
Note Added in Proof. Cheng et al. (41) have described the isolation of a highly potent fragment of PKI that would correspond to PKI-(5-25)-peptide in the present paper. A subsequent study (42) reported the inhibitory properties of a series of synthetic peptide analogues patterned after the inhibitory site. Except for some variations in the absolute values of the inhibitory constants, the results of the latter study are reasonably comparable to those reported here.
